MVA-BN-HER2
AXP000186.1 · Cancer vaccine
- Platform
- MVA-BN
- Targets
- ERBB2
- Originator
- Bavarian Nordic
- Sponsor
- Bavarian Nordic
Names
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- MVA-BN
- Replication
- non replicating
- Modifications
- HER2 antigen cassette inserted into MVA-BN
- Transgenes
- ERBB2
- Source
- evidence
Cross-references
- NCI Thesaurus
- C71758
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT01152398 | A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy | Completed | Phase 1 | 2010-06 | 2012-09 | 15 | Breast Cancer |
| NCT00485277 | A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer | Completed | Phase 1 | 2007-06 | 2010-09 | 9 | Breast Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 26910562 | Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice. | PloS one | 2016 | name in abstract: MVA-BN-HER2 |
| PMID 26961085 | Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. | Cancer immunology, immunotherapy : CII | 2016 | name in abstract: MVA-BN-HER2 |
| PMID 21822917 | Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. | Cancer immunology, immunotherapy : CII | 2012 | name in title: MVA-BN-HER2 |
Notes
MVA-BN encoding a modified HER2 (ERBB2) antigen; early-phase trials in HER2-expressing cancers. Exact antigen construct (HER2 epitope string vs full-length) and current status not verified here.
How to cite
MVA-BN-HER2 (AXP000186.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000186.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.